FOXM1 is a member of the fork head/winged-helix (FOX) transcription factor family and at first is found to activate a network of proliferation-associated genes critical to DNA replication and mitosis 1, 2 . FOXM1 is frequently overexpressed in multiple cancers through the activation of specific transcriptional pathways 3 . As a consequence, FOXM1 is linked with many tumorigenesis processes, such as oxidative stress response 4 , DNA damage repair 5 , cancer stem cell proliferation 6 , and metastasis 7, 8 . The inhibition of FOXM1 expression or its activities abolishes the tumorigenesis and is suggested as a novel therapeutic strategy in cancer treatments [9] [10] [11] [12] [13] [14] . FOXM1 activates gene transcription processes through its binding to its target gene promoters. Like the other members of FOX family, FOXM1 contains a highly conserved 100-aa DNA binding domain (DBD), which binds to a consensus DNA sequence containing a canonical FKH motif (RYAAAYA) in the promoters of its target genes 15 . Therefore, the attenuation of the DNA binding ability of FOXM1 could suppress FOXM1 transcriptional activities and represent a potent strategy targeting FOXM1 in cancer cells 16 . Aptamers are single-stranded oligonucleotides obtained from a combinatorial oligonucleotide library through a method referred to the systematic evolution of ligands by exponential enrichment (SELEX) 17, 18 . The selected single-stranded oligonucleotides are capable of specific and high-affinity binding to target molecules due to their tertiary structures 19 . Compared with conventional antibodies, aptamers recognize their target molecules with a number of attractive features, including low molecular weight, quick and reproducible synthesis in vitro, easy modification, good stability, low toxicity, low immunogenicity, and rapid tissue penetration 20 . The aptamers selected directly against proteins can interfere with their target protein activities and are good tools to be used to investigate the mechanisms of protein-protein and/or protein-nucleic acids interaction. These advantages have also made aptamers excellent alternatives for diagnostic and/or therapeutic purposes in disease treatment 21 . So far, several small-molecule inhibitors of FOXM1 have been obtained but none of them are good enough for clinical usage 9, 10, 14 , requiring the development of novel FOXM1 inhibitors. In this study, we obtained a
The phosphorthioate-modified FOXM1 Apt (M-FOXM1 Apt) maintained the binding activities to FOXM1 protein. Wild -type DNA aptamers are too susceptible to nuclease-mediated degradation to be useful for in vivo applications 20 . Among multiple approaches for modifying oligonucleotides, we chose internucleotide phosphorothioate linkage modification 22 for FOXM1 Apt. The internucleotide linkages of FOXM1 Apt were modified by the sulfur substitution in the phosphate ester backbone to form phosphorothioate linkages ( Fig. 2A) . As the consequence of phosphorothioate modification, the molecular mass of the modified FOXM1 Apt (M-FOXM1 Apt) was elevated in the measurement of mass spectrometry (Fig. S4A) . The M-FOXM1 Apt possessed a similar spatial structure as the FOXM1 Apt, evidenced by the Circular Dichroism (CD) measurement in the parallel structure formation for the FOXM1 Apt and M-FOXM1 Apt, although M-FOXM1 Apt showed enhanced negative peaks at 211 nm and 248 nm and an elevated positive peak at 277 nm (Fig. S4B) . M-FOXM1 Apt obtained an enhanced stability in the DNase I treatment compared to FOXM1 Apt (Fig. S4C) . The EMSA Apt)  TCA CTT CAC ACC GCA TCT CTA  CGT CCG GTT GCG CTT TCC TTT  17  42.5%   C2  TCC CAG TCA CGA CGT TGT AAA  ACG ACG GCC AGT GAA TTG TAG  8  20%   C3  CTG AAA GCG CAA CCG GAC GTA  TAC AAG CGG GGG TCC TTG ATT  6  15%   C4  TTA CTG GAG CCC CGC ATC ACT  GCG ATC CGG GTG CGG TTC CCT  6  15% Other sequences 7.5% Table 1 . The sequences of selected colonies (n = 40) from the sixth round of SELEX.
Scientific RepoRts | 7:45377 | DOI: 10.1038/srep45377 The FOXM1 Apt bound to FOXM1 DBD specifically in the EMSA experiment. The ROX-labeled FOXM1 Apt (FOXM1 Apt-F) (50 nM) was used for EMSAs with the purified GST or GST-FOXM1 DBD fusion proteins (0.5 mg/ml). The unlabeled FOXM1 Apt (100x) was added to the reaction to show specificity of FOXM1 Apt/GST-FOXM1 DBD complex formation. The ROX-labeled Control Apt (Control Apt-F) (50 nM) or the FAM-labeled double strand DNA probe containing FOXM1 putative binding sequence (dsDNA probe-F) (50 nM) was also used for EMSAs with GST or GST-FOXM1 DBD fusion proteins as the negative or positive controls respectively in the assays. (B) Detection of the binding affinity between FOXM1 Apt and FOXM1 DBD. The fluorescence polarization (FP) assays were performed with FOXM1 Apt-F, Control Apt-F, or dsDNA probe-F (10 nM each sample) plus the FOXM1 DBD protein at different concentration (0, 120, 240, 960, 1440, 1920 nM). The FP values were obtained with the EX535 nm/EM600 nm filter for ROX or the EX405 nm/EM535 nm filter for FAM in Fluoromax-4NIR (Horiba). (C,D) Identification of the binding ability and affinity of FOXM1 Apt to FOXM1 full-length protein. FOXM1 Apt-F (50 nM) was used for EMSA experiments with the purified His-FOXM1 full-length protein (FOXM1) (0.5 mg/ml). The unlabeled FOXM1 Apt (100x) was added to the reaction to show specificity of FOXM1 Apt/FOXM1 complex formation. Control Apt-F (50 nM) or dsDNA probe-F (50 nM) was also used for EMSAs with His-FOXM1 full-length protein as the negative or positive controls respectively in the assays (C). The FP assays were performed with FOXM1 Apt-F, Control Apt-F, or dsDNA probe-F (50 nM) plus the His-FOXM1 protein at different concentration (0, 240, 480, 720, 960 nM). The FP values were obtained according to the procedure described above. Data shown are the mean values of three assay points (± S.E.M.).
experiments were performed with ROX-labeled M-FOXM1 Apt (M-FOXM1 Apt-F) and FOXM1 DBD or FOXM1 full-length protein, and confirmed that M-FOXM1 Apt maintained the binding activities to FOXM1 protein (Fig. 2B,C) . The FP assays determined that the K D of M-FOXM1 Apt-F to FOXM1 full-length protein was 63.86 ± 6.6 nM (Fig. 2D) , implicating that the phosphorthioate modification in FOXM1 Apt even improved its binding affinity to FOXM1 proteins compared to wild-type FOXM1 Apt (FOXM1 Apt to FOXM1 protein: K D = 172.1 ± 26.55 nM, see above). Therefore, we used M-FOXM1 Apt-F for further experiments.
M-FOXM1 Apt bound to FOXM1 protein specifically in cancer cells. There are more than 50 members identified in FOX transcription factor family and all of them contain a highly conserved DBD. Because FOXM1 Apt was selected by using FOXM1 DBD as the target molecule in SELEX, we had to determine whether the binding of FOXM1 Apt to FOXM1 was highly specific. We tested whether or not M-FOXM1 Apt was able to bind to other FOX proteins such as FOXA2, which is the first cloned mammalian FOX transcription factor containing the typical conserved DBD 23 . A His-FOXA2 full-length protein was purified (Fig. S5 ) and used for EMSAs with M-FOXM1 Apt. In the same experimental condition, M-FOXM1 Apt bound to FOXM1 but not FOXA2 (Fig. 3A) . To further test that FOXM1 Apt could recognize FOXM1 specifically from a mixture of cellular proteins, we first prepared whole-cell lysates from the FOXM1-overexpressing cells in which FOXM1 expression plasmid vectors were transfected (Fig. S6A) . As a control, the lysate of the FOXA2-overexpressing cells was also prepared (Fig. S6B) . Biotinylated M-FOXM1 Apt (M-FOXM1 Apt-biotin) was generated and incubated with FOXM1-overexpressing or FOXA2-overexpressing cell lysates. Streptavidin agarose beads were added to the reactions to pull down M-FOXM1 Apt-biotin/protein complexes, which were detected by Western Blotting only in the reaction of M-FOXM1 Apt-biotin plus FOXM1-overexpressing lysates (Fig. 3B) , suggesting a specific interaction between FOXM1 Apt and FOXM1 proteins in the complicated conditions. We then prepared lysates from MDA-MB-436 breast cancer cells endogenously expressing both FOXM1 and FOXA2, and repeated the experiments described above to confirm the specific interaction between FOXM1 Apt and FOXM1 proteins in the cancer cells (Fig. 3C) . The specificity of the binding of FOXM1 Apt to FOXM1 proteins was further determined by Pull-down experiments with MDA-MB-436 cell lysates in which the endogenous FOXM1 expression was knocked down by the transfection of pFOXM1-shRNA vectors to the cells (Fig. 3C) . Furthermore, to confirm the recognition of FOXM1 Apt to FOXM1 proteins in cells, we transfected HEK293T cells with pCMV-FOXM1-GFP plasmids expressing FOXM1-GFP fusion proteins, followed by the transfection of M-FOXM1 Apt-F one day later. Observed under a fluorescent Con-focal microscope, FOXM1-GFP fusion proteins localized in nuclei of cells (Fig. 3D ). Compared to Control Apt that stayed in the cytosol of cells, FOXM1 Apt was found to co-localize with FOXM1 proteins in nuclei of cells (Fig. 3D ), suggesting that FOXM1 Apt could specifically bind to FOXM1 in cells. As a control experiment, HEK293T cells were also transfected with pCMV-FOXA2-GFP plasmids expressing FOXA2-GFP fusion proteins, followed by the transfection of M-FOXM1 Apt-F. We found that the FOXA2-GFP fusion proteins localized in nuclei but FOXM1 Apt stayed in cytoplasm, confirming no interactions between FOXM1 Apt and FOXA2 (Fig. 3D ).
FOXM1 Apt suppressed the transcriptional activities of FOXM1. FOXM1 is linked to various types
of human malignancies through stimulating the expression of cancer cell-related target genes 3 . The transcriptional activation of FOXM1′ s target genes requires FOXM1 binding to its target gene promoters 15 . To test whether FOXM1 Apt could affect FOXM1 transcriptional activities, we first performed EMSAs and determined that M-FOXM1 Apt abolished the binding ability of FOXM1 to its putative DNA binding sequence dramatically in vitro, at a dose-dependent manner (Fig. 4A) . The wild type FOXM1 Apt also showed similar inhibitory effects on the FOXM1-DNA binding ability as M-FOXM1 Apt (Fig. S7) . Based on previous studies 15, 24 , the cotransfection of FOXM1 expression vector in cells could stimulate the promoter activities of the luciferase reporter plasmids, whose luciferase expression was controlled by either an artificial 6x FOXM1 binding sequence-containing promoter or an endogenous − 2.3 kb promoter of Cdc25B (FOXM1′ s target gene) (Fig. 4B) . The addition of FOXM1 Apt or M-FOXM1 Apt to the cotransfection inhibited the FOXM1-mediated stimulation on the promoter activities significantly while M-FOXM1 Apt appeared better effects than the wild type FOXM1 Apt (Fig. 4B) , demonstrating that FOXM1 Apt was able to prevent FOXM1 transcriptional activities in vivo. The control aptamer M-Control Apt did not affect FOXM1 transcriptional activities in the cells (Fig. 4B) .
FOXM1 Apt suppressed cell growth through inhibiting the expression of proliferation-related target genes of FOXM1. To test whether FOXM1 Apt could potentially disturb the proliferation of cancer cells through abolishing FOXM1 transcriptional activities, we first generated a cancer cell line stably overexpressing FOXM1 (293T-FOXM1 cells), in which the consequences of the loss-function of FOXM1 were easily observed. The transfection of M-FOXM1 Apt to 293T-FOXM1 cells resulted in the decrease of cell viabilities at a dose-dependent manner by MTT analysis (Fig. 5A) . Interestingly, the transfection of pFOXM1-shRNA vectors expressing FOXM1-specific interference shRNA to the cells also caused similar effects (Fig. 5A) , implicating that the ability of M-FOXM1 Apt disturbing the functions of FOXM1 was as powerful as that of the FOXM1 RNA interference. The results of the growth curve and morphological changes from M-FOXM1 Apt-treated 293T-FOXM1 cells also supported this conclusion (Fig. 5B,C) . Flow cytometry was used to analyze cell cycle and further showed the disturbed cell proliferation in M-FOXM1 Apt-treated cells (Fig. 5D ). To test whether FOXM1 Apt affected the expression of FOXM1 and its target genes, we measured the levels of the mRNA and protein for FOXM1, Cdc25B, and Cyclin B1, among which the last two are FOXM1-stimulated genes 24, 25 , at the 48 hr time point post the M-FOXM1 Apt treatment. As predicted, the transfection of pFOXM1-shRNA vectors in 293T-FOXM1 cells resulted in the down-regulation of the expression of FOXM1 target genes Cdc25B and Cyclin B1, correlated with the knockdown of FOXM1 mRNA and protein levels (Fig. 5E,F) . On the other hand, the treatment of M-FOXM1 Apt at the high dosage in 293T-FOXM1 cells also caused a dramatic down-regulation of the expression of Cdc25B and Cyclin B1 without changing the levels of FOXM1 mRNA and protein in the cells (Fig. 5E,F) , implicating that the inhibitory effects of FOXM1 Apt on FOXM1 resulted from disturbing FOXM1 transcriptional activation function but not from affecting FOXM1 expression. As a control, we also tested whether the proliferation of wild type 293T cells with a very low endogenous FOXM1 expression was affected by FOXM1 Apt. The M-FOXM1 Apt treatment at the dosage (500 nM) that abolished the proliferation of 293T-FOXM1 cells did not show dramatic effects on 293T cells (Fig. S8 ). In addition, we treated MDA-MB-436 breast cancer cells with M-FOXM1 Apt and measured the levels of FOXM1, Cdc25B, and Cyclin B1. The treatment of M-FOXM1 Apt caused a dramatic down-regulation of the expression of Cdc25B and Cyclin B1 without obvious changing of FOXM1 levels in MDA-MB-436 cells (Fig. 5G,H) . Taken together, these results determined that FOXM1 Apt could suppress the cellular proliferation of cancer cells by abolishing the functions of FOXM1 in vivo.
Discussion
Aptamers have been suggested as diagnostic or therapeutics reagents because of their high affinity and specificity towards selected targets and abolishing the functions of their targets without obvious side-effects 20 . In 2005, FDA approved Macugen, a RNA aptamer targeting VEGF, as the first aptamer therapeutic for age-related macular degeneration or diabetic retinopathy 21 . A number of aptamer-based therapeutics are currently undergoing clinical trials, including therapeutic aptamers for cancer treatment such as AS1411 targeting nucleolin 26 and NOX-A12 targeting stroma cell-derived factor-1 (SDF-1) 27 . An aptamer specific for modulating the function of intracellular transcription factor NF-κ B has been developed and shows effective inhibition of NF-κ B in vitro and in vivo 28, 29 , suppressing non-small cell lung cancer resistance to Doxorubicin 30 . An aptamer that inhibits the function of the E2F family of transcription factors has also been obtained and can be potentially used for preventing tumor development 31 . In this study, we obtained the FOXM1-specific single stranded DNA aptamer FOXM1 Apt to target FOXM1 DBD and full-length protein specifically. FOXM1 Apt was confirmed to prevent the binding of FOXM1 to its consensus binding sites in promoters and consequently suppress FOXM1 transcriptional activities, resulting in the downregulation of the expression of FOXM1 target genes and the inhibition of cancer cell proliferation.
FOXM1 is ubiquitously expressed in proliferating and regenerating mammalian cells 1 and is a key cell cycle regulator of both the transition from G1 to S phase and the progression to mitosis by regulating transcription of cell cycle genes 2 . Loss of FOXM1 expression causes diminished DNA replication 32 , mitotic spindle defects 33 , and mitotic catastrophe 34 . Furthermore, we and others have shown that FOXM1 is involved in contra-acting stresses induced by cytotoxic or genotoxic signals, such as oxidative stress or DNA damage, and enhances the drug resistance of cancer cells 35 . Moreover, we have characterized that FOXM1 plays an essential role in maintenance of cell stemness and its expression is absent from differentiated cells 36, 37 . These observations suggest that FOXM1 is associated with cancer initiation and progression through its critical roles in cell proliferation, drug resistance, and malignant transformation of undifferentiated cells. This notion is apparently supported by the fact that FOXM1 is highly expressed in various types of human malignancies, such as lung cancer 38 , prostate cancer 39 , basal cell carcinomas 40 , hepatocellular carcinoma 41 , gastric cancer 42 , and squamous cell carcinoma 43 , demonstrating FOXM1 as a diagnostic marker for monitoring the initiation and progression of multiple human cancers. The inactivation of FOXM1 leads to inhibition of progression and/or invasion of these cancers, suggesting FOXM1 as an attractive target for the development of novel anti-cancer therapies. Small chemical compounds and FOXM1-specific RNA interference adenovirus vectors has been developed to inhibit FOXM1 functions for cancer treatment [9] [10] [11] [12] [13] [14] . It is necessary to explore more FOXM1-targeting therapeutic strategies that would finally reach the stage of clinical usage. Therefore, FOXM1 Apt obtained from this study provided a potential reagent to detect and repress FOXM1 at the same time, good for cancer diagnosis and treatment in the future.
We confirmed the specificity of FOXM1 Apt binding to FOXM1 by showing that the aptamer was not able to bind to FOXA2, which also contains the typical conserved DBD of FOX transcription factors. In addition, we found that FOXM1 Apt could not interact with FOXP2, another member of FOX transcription factors, in the pull-down experiments with FOXM1 Apt and MDA-MB-436 cell lysates (data not shown). To understand how FOXM1 Apt recognizes FOXM1, we predicted the secondary structure of the aptamer that comprises a primarily stem-loop-loop structure (Fig. S9A) . We generated three truncated aptamers, FOXM1 Apt (1-15 nt), FOXM1 Apt (11-34 nt) and FOXM1 Apt (28-42 nt), based on the structural motifs of FOXM1 Apt (Fig. S9B) . Even though (1 μ g) was cotransfected with a luciferase reporter plasmid containing 6x FOXM1 binding sequences in its promoter (p6xFOXM1 Binding-Luc, 1 μ g) or a − 2.3 kb Cdc25B promoter-luciferase reporter plasmid (pCdc25B promoter-Luc, 1 μ g) plus loading control pRL-CMV luciferase reporter plasmid (20 ng) into HEK293T cells. M-Control Apt, FOXM1 Apt, or M-FOXM1 Apt (500 nM each sample) was added to the selected transfection. Protein lysates were prepared at 48 hr after transfection and used for the measurement of dual Luciferase activities. Data shown are the mean values of three assay points (± S.E.M.). The asterisks indicate statistically significant changes to the positive control sample (pCMV-FOXM1 only): *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001. the CD measurement could not tell obvious differences in spatial structures among these truncated aptamers (Fig. S9C) , EMSA experiments with FOXM1 full-length protein confirmed that only the truncated FOXM1 Apt (11-34 nt) possessed FOXM1-binding activities but much weaker than that of wild-type FOXM1 Apt (Fig. S9D) . This finding suggested that the 11-34 nt sequence of FOXM1 Apt was the core binding sequence mediating the interaction between FOXM1 Apt and FOXM1 protein. Aptamers often bind to functionally important parts of target proteins and affect protein-protein or protein-nucleic acid interaction of the target proteins 20 . It is still a challenge to predict the binding structure of an aptamer recognizing its target protein according to its nucleotide sequence, resulting in that pharmacokinetic and other systemic properties of the aptamer are variable and often hard to be predicted in practice. With the solved crystal structure of FOXM1 DBD and FOXM1 protein 15 , our study provided a suitable pair of molecules FOXM1 Apt and FOXM1 protein to learn the detail mechanisms how FOXM1 Apt interacting with FOXM1. Further research will concentrate on the analysis of FOXM1 Apt-FOXM1 DBD crystal structure, identify the key nucleotide(s) and conformations of FOXM1 Apt to mediate the interaction between the two molecules, and hopefully provide clues to predict or even design aptamers for target proteins in the future.
In general, native ssDNA aptamer molecules are too susceptible to nuclease-mediated degradation to be useful for most therapeutic applications. When unmodified aptamers enter the cell or are administered in vivo, they are rapidly degraded by nucleases 20 . Therefore, chemical modifications of the oligonucleotides are often required to increase resistance to degradation by nucleases. Several strategies have been developed to increase the stability of aptamers without compromising the binding affinity and specificity towards their targets. The nucleotides of aptamers can be partially or completely substituted with one or more modifications, including 2′ -amino pyrimidines 44, 45 , 2′ -fluoro pyrimidines 46 , and 2′ -O-methyl ribose purines and pyrimidines 47 . Internucleotide linkages can also be modified to phosphorothioate linkages 22 and high molecular mass polyethylene glycol (PEG) can be conjugated to the 5′ -terminus 48 . In this study, we chose to modify the internucleotide linkages of FOXM1 Apt to phosphorothioate linkages. The modified M-FOXM1 Apt possessed a similar spatial structure as FOXM1 Apt and obtained an enhanced resistance to nuclease-mediated degradation. M-FOXM1 Apt imparted greater affinities to FOXM1 protein compared to wild-type FOXM1 Apt, consistent to other findings that sulfur substitution of , M-FOXM1 Apt (100 nM, 300 nM, 500 nM), or pFOXM1shRNA (300 nM) and 48 hr later the cell samples were harvested for the preparation of total RNA and total proteins. The levels of FOXM1, Cdc25B, and Cyclin B1 in the cells were examined by qPCR for mRNA levels (E) and by Western blotting for protein levels (F). (G,H) MDA-MB-436 breast cancer cells were transfected with M-Control Apt (500 nM), M-FOXM1 Apt (500 nM), or pFOXM1shRNA (300 nM) and 48 hr later the cell samples were harvested for the preparation of total RNA and total proteins. The levels of FOXM1, Cdc25B, and Cyclin B1 in the cells were examined by qPCR for mRNA levels (G) and by Western blotting for protein levels (H). Data shown are the mean values of three assay points (± S.E.M.). The asterisks indicate statistically significant changes to the M-Control Apt-treated control sample: *P ≤ 0.05 and **P ≤ 0.01. the phosphate ester backbone in aptamers often results in enhanced binding to their target proteins 22 . Whether M-FOXM1 Apt shows better performance to detect and/or repress FOXM1 in animal models than FOXM1 Apt needs be further evaluated.
In conclusion, the obtained FOXM1 Apt from this study could selectively bind to FOXM1 protein, co-localize with FOXM1 in nucleus after entering cells, and potentially abolish the binding abilities of FOXM1 to its target gene promoters. By this way, the transfection of FOXM1 Apt results in the downregulation of the expression of FOXM1 target genes in cells and consequently inhibits cancer cell proliferation. FOXM1 Apt is a novel and specific FOXM1 inhibitor, providing a potential reagent for cancer diagnosis and therapy in the future.
Methods
Cell Culture. HEK 293T and MDA-MB-436 cells were obtained from ATCC and HEK 293T-FOXM1 stable cell line was preserved in our laboratory 8 . HEK 293T and HEK 293T-FOXM1 cells were grown in Dulbecco's Modified Eagle Media (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA). MDA-MB-436 cells were grown in Leibovitz's L15 (Gibco, USA) supplemented with 10% fetal bovine serum (Gibco, USA). All cells were cultured in a 5% CO2-humidified atmosphere at 37 °C.
Construction of Plasmids. FOXM1 DBD cDNA (225-355 aa) was PCR amplified from pCMV-FOXM1 full length plasmid 36 with primers containing BamHI and EcoRI restriction sites (sense primers: 5′ -GCG GAT CCC CAT CAG CGT CCT GGC AGA A-3′ and antisense primers: 5′ -GC GAA TTC CTA CAG TGG CTT CAT CTT CCG-3′ ) and ligated into the pGEX-4T-1 vector. FOXM1 FL (full length) cDNA was PCR amplified from pCMV-FOXM1 plasmid with primers containing BamHI and XbaI restriction sites and the Shine-Dalgarno sequence (AGGAGG) before the ATG (sense primers: 5′ -GCT CTA GAA AAG GAG GAC AGC TAT GAA AAC TAG CCC CCG TCG GC-3′ and antisense primers: 5′ -GCG GAT CCC TAG TGA TGG TGA TGG TGA TGC TGT AGC TCA GGA ATA A-3′ ) and ligated into the pET-15b vector. FOXA2 FL (full length) cDNA was PCR amplified from pCMV-FOXA2 plasmid 49 with primers containing XbaI and BamHI restriction sites and the Shine-Dalgarno sequence (AGGAGG) before the AUG (sense primers: 5′ -GCT CTA GAA AAG GAG GAC AGC TAT GCA CTC GGC TTC CAG TAT-3′ and antisense primers: 5′ -GCG GAT CCC TAG TGA TGG TGA TGG TGA TGA GAG GAG TTC ATA ATG GG-3′ ) and ligated into the pET-15b vector. FOXM1 cDNA was PCR amplified from pCMV-FOXM1 plasmid with primers containing BamHI and XbaI restriction sites (sense primers: 5′ -GCG GAT CCA TGA AAA CTA GCC CCC GTC GGC-3′ and antisense primers: 5′ -GCT CTA GAC TAC TGT AGC TCA GGA ATA A-3′ ) and ligated into the pEGFP-C2 vector. FOXA2 cDNA was PCR amplified from pCMV-FOXA2 plasmid with primers containing EcoRI and BamHI restriction sites (sense primers: 5′ -GGA ATT CAT GCA CTC GGC TTC CAG TAT-3′ and antisense primers: 5′ -CGG GAT CCT TAA GAG GAG TTC ATA ATG-3′ ) and ligated into the pEGFP-C2 vector. The p6xFOXM1 Binding-Luc report plasmid was constructed by ligating a DNA fragment (NheI 5′ -GCG CGC TAG CTT TGT TTA TTT GTT TGT TTA TTT GTT TGT TTA TTT GAA GCT TGC GC-3′ HindIII) into the pGL3 basic Luciferase vector (Promega, USA).
Expression and Purification of Recombinant Proteins. Certain plasmids were transformed into
Rosetta/DE3 E. Coli cells and positive colonies were confirmed by colony PCR screening. Cells were grown at 37 °C in LB media until reaching an optical density (OD 600 ) of 0.8 and protein expression was induced by addition of 1 mM IPTG for additional 6 hr at 37 °C. The GST protein and GST-FOXM1 DBD protein were purified by Glutathione Sepharose TM 4B (GE, USA) following the manufacturer's instructions. The FOXM1 FL protein and FOXA2 FL protein were purified by Ni-Sepharose TM 6 Fast Flow (GE, USA) following the manufacturer's instructions.
Aptamer Selection by SELEX. Single-stranded DNA (ssDNA) aptamers recognizing FOXM1 DBD were identified using the PCR-based SELEX method 17 . Briefly, a synthetic ssDNA library, containing random 42 nucleotides flanked by 20 nt at each end (5′ -AG CAA TGG TAC GGT ACT TCC-42N-GTG CCA CGC TAC TTT GCT AA-3′ ), was synthesized by Sangon (Shanghai) Co., Ltd, China. The ssDNA library (100 μ M, 20 μ l, ~2.14 × 10 15 sequences) was mixed with 500 μ l binding buffer (20 mM Hepes, 120 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , pH 7.35) and heated at 95 °C for 5 min and snap-cooled on ice. GST-FOXM1 DBD protein (10 μ g) and Glutathione SepharoseTM 4B beads (50 μ l, GE, USA) were added and mixed thoroughly and incubated on ice for 1 hr in a rotary shaker. The mixture was centrifuged at 8000 rpm for 5 min at 4 °C and the pellets was washed twice with binding buffer. The pellets were resuspended with 500 μ l binding buffer, heated at 95 °C for 10 min, centrifuged at 13,100 g for 5 min. The collected supernatant was mixed with GST protein (10 μ g) and Glutathione SepharoseTM 4B beads (50 μ l, GE, USA) and incubated on ice for 1 hr in a rotary shaker. The mixture was centrifuged at 8000 rpm for 5 min at 4 °C to remove the pellet containing non-specific binding ssDNAs. The supernatant was collected and amplified by PCR with the primers (forward: 5′ -ROX-A GCA ATG GTA CGG TAC TTC C-3′ and reverse: 5′ -Biotin-T TAG CAA AGT AGC GTG GCA C-3′ ). The PCR products were incubated with streptavidin agarose beads (GE, USA) for 30 min at room temperature and washed 3 times with PBS. The biotin-labeled reverse strand of DNA products were eluted by adding NaOH (1.5 M) and considered as the selected ssDNA pool for the next round of SELEX. After the 6 rounds of selection, the enriched PCR products were cloned with TOPO TA cloning kit (Invitrogen, USA) and the colonies were selected for DNA sequencing. Luciferase Activity Assays. 293T cells (2 × 10 5 cells per well in a 6-well plate) were cotransfected with luciferase reporter constructs (p6xFOXM1 Binding-Luc or pCdc25B promoter-Luc) (1 μ g) and pCMV-FOXM1 (1 μ g). The pRL-CMV plasmid (20 ng) was used as the loading control for each transfection. Control Apt (500 nM) or FOXM1 Apt (100, 300, 500 nM) was also added to certain transfections to test the effects of the aptamers. The luciferase enzyme activities were measured 48 h later with the Dual-Luciferase Assay System (Promega, USA) following the manufacturer's instructions.
Pull-Down Assays. Biotinylated aptamers (5 μ M) were incubated overnight with cell extracts (500 μ g) at 4 °C by end-to-end rotation. Streptavidin agarose beads (20 μ L, GE, USA) were applied to samples for 2 hr incubation and the beads were washed three times in lysis buffer (50 mM Tris-Cl, 100 mM NaCl, 2.5 mM EDTA, 2.5 mM EGTA, 1% NP-40, 5% Glycerol). Samples were separated by PAGE and transferred onto PVDF membrane (Millipore, USA). The membrane was blocked with 5% milk and Western Blotting were performed to detect target proteins.
Isolation RNA, Reverse Transcription and Quantitative Real-time PCR. The total RNA was isolated by Total RNA Kit (Omega, USA) according to the manufacturer's protocols. The cDNAs were synthesized with M-MLV Reverse Transcriptase (Promega, USA) from total RNA samples. qPCR was performed with SYBR Green (Toyobo, Japan) with following sense (S) and antisense (AS) primers: hFOXM1-S, 5′ -GCT TGC CAG AGT CCT TTT TGC-3′ and hFOXM1-AS, 5′ -CCA CCT GAG TTC TCG TCA ATG C-3′ ; hCdc25B-S, 5′ -AGT CCT GAC CGG AAG ATG GA-3′ and hCdc25B-AS, 5′ -GAT GTT GCT GAA CTT GCC CG-3′ ; hCyclinB1-S, 5′ -GGT CTG GGT CGG CCT CTA CCT-3′ and hCyclinB1-AS, 5′ -AGC CAG GTG CTG CAT AAC TGG AA-3′ ; hGAPDH-S, 5′ -GGA GCG AGA TCC CTC CAA AAT-3′ and hGAPDH-AS, 5′ -GGC TGT TGT CAT ACT TCT CAT GG-3′ . The qPCR was performed in the realplex2 qPCR system (Eppendorf, Germany).
Western Blot Assays. Whole-cell lysates were separated using SDS-PAGE and transferred onto PVDF membrane for western blotting. The following antibodies and dilutions were used for Western blotting: rabbit anti-FOXM1 (1:5000, SantaCruz sc-502), rabbit anti-Cdc25B (1:1000, SantaCruz sc-326), mouse anti-CyclinB1 (1:1000, SantaCruz sc-166757), mouse anti-β -actin (1:10000, Abcam ab49900). The signals from the primary antibody were amplified by horseradish peroxidase (HRP) conjugated anti-rabbit IgG (1:10000, GE LNA934VAE) or anti-mouse IgG (1: 10000; BioRad 170-6516), and detected with Super Signal West Femto Maximum Sensitivity Substrate (Thermo, USA) by Kodak 4000 MM Imaging System (Kodak, USA).
Circular Dichroism (CD) Measurement. Aptamers (5 μ M) were resuspended in binding buffer (20 mM Tris-Cl, 50 mM KCl, 10% glycerol, 0.5 mM EDTA, 0.2 mM DTT, pH 7.6), heated at 95• C for 5 min, and snap-cooled on ice. CD spectra were collected on a MOS-500 Spectrometer (Biologic, France) equipped at 200-350 nm, 0.2 s Acq duration, 4 nm Fentes bandwidth.
Flow cytometry analysis of cell cycle. The tested cells were collected and washed twice with cold PBS.
Cells were fixed overnight in 70% ethanol at 4°C and collected by centrifugation 3,000 r.p.m. for 2 min. The cell pellets were resuspended in propidium iodide (0.05 mg/ml) plus RNase (0.02 mg/ml) and incubated in the dark at room temperature for 30 min. The cells were filtered and analyzed for DNA content on a QuantaSC flow cytometer (Beckman, USA).
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Statistical Analysis. The experimental data are expressed as the mean ± standard deviation. The comparison among groups was performed using one-way analysis of variance and Dunnett-t tests were used for comparison between experimental groups and control groups. P < 0.05 was considered to indicate a statistically significant difference.
